-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Biopharmaceutical company Aptorum recently announced that it has obtained permission from Health Canada to begin phase I research on ALS-4.
ALS-4 is a new type of oral small molecule.
ALS-4 may reduce antimicrobial resistance by reducing selection pressure and making bacteria susceptible to host immunity removal.
the goal of ALS-4 is to treat methicillin-resistant Staphylococcus aureus (MRSA) infection, 1 alone or in combination with other existing antibiotics such as vancomycin.
methicillin-resistant Staphylococcus aureus (MRSA) is a unique strain of Staphylococcus aureus that is resistant to almost all penicillin antibiotics, including methicillin and other penicillins that are resistant to β endamidease.
first discovered in the UK in 1961 and is now widely known as a "superbug".
Aptorum plans to conduct Phase I clinical trials in Canada, with the goal of recruiting 48 and 24 healthy volunteers to participate in single incremental dose (SAD) and multiple incremental dose (MAD) queues, respectively.
the main purpose of the trial was to assess the safety and tolerance of oral ALS-4 to healthy subjects.
secondary purpose is to evaluate the pharmacological dynamics characteristics of ALS-4.